| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:SIJ1777
CAS:839707-55-0
Purity:99.96% Package:50mg/RMB 15300;10mg/RMB 7880
|
|
| | Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- Basic information |
| | Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- Chemical Properties |
| density | 1.45±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 12.82±0.70(predicted) |
| | Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- Usage And Synthesis |
| Uses | SIJ1777 is a GNF-7 (HY-10943) derivative, possesses potent anti-cancer effects on melanoma cells harboring BRAF class I/II/III mutations. SIJ1777 substantially inhibits the activation of MEK, ERK, and AKT. SIJ1777 remarkably induces apoptosis and significantly blocks migration, invasion, and anchorage-independent growth of melanoma cells harboring BRAF class I/II/II mutations[1]. | | References | [1] Kim N, et al. Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance. Int J Mol Sci. 2021 Apr 6;22(7):3783. DOI:10.3390/ijms22073783 |
| | Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- Preparation Products And Raw materials |
|